Day: March 7, 2024

Fourth Quarter Revenue Increased 15% to $15.1 Million Producing $4.2 Million of Cash Flow from Operations Full Year 2023 Revenue Increased 13% to $60.2 Million Generating Net Income of $13.5 Million BOCA RATON, Fla., March 07, 2024 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter and full year ended December 31, 2023. “We delivered a solid quarter, capping off another record year for red violet that produced records in revenue, gross profit, net income, adjusted EBITDA, cash flow from operations, and free cash flow,” stated Derek Dubner, red violet’s CEO. “Our industry-leading AI/ML-powered platform, proprietary linking algorithms, and core identity graph continue to drive our excellence in entity resolution that is pivotal...

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business HighlightsQ4-2023 recurring revenue growth of 60% over Q4-2022. TULSA-PRO® systems installed base now totals 50; Profound continues to expect to grow that to 75 TULSA-PRO® systems in 2024. To date, TULSA-PRO® has been installed at, or contracted...

COSTA MESA, Calif., March 07, 2024 (GLOBE NEWSWIRE) — El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended December 27, 2023. Highlights for the fourth quarter ended December 27, 2023 compared to the fourth quarter ended December 28, 2022 were as follows:Total revenue was $112.2 million compared to $115.9 million. System-wide comparable restaurant sales(1) increased 0.9%. Income from operations was $7.5 million compared to $9.5 million. Restaurant contribution(1) was $14.8 million, or 15.8% of company-operated restaurant revenue, compared to $14.7 million, or 14.7% of company-operated restaurant revenue. Net income was $4.4 million, or $0.14 per diluted share, compared to net income of $6.5 million, or $0.18 per diluted share. Adjusted net income(1) was $5.2 million, or $0.16 per...

– Announces $15 Million Increase to Share Repurchase Plan – DENVER, March 07, 2024 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., reported financial results for the first quarter ended January 31, 2024. First Quarter Fiscal Year 2024 Summary vs. First Quarter of Fiscal Year 2023 (unless otherwise noted)  ● Revenue increased 4% to $97.7 million compared to $93.6 million.  ● Gross profit decreased 9% to $33.3 million compared to $36.5 million.  ● Income from operations decreased to $1.5 million compared to $9.4 million.  ● Net loss of $3.8 million compared to net income of $6.5 million.  ● Net loss attributable to common shareholders of $4.3 million or $(0.08) per diluted...

Fourth quarter same-store sales growth of 6.3% and AWS of $24,960, with traffic growth as a major driver 202 new shop commitments to-date under the Franchise Growth Acceleration Initiative Provides first quarter and full year 2024 outlook; Introduces new long-term growth ranges CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) — Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood sandwich shop concept, today reported financial results for its 14-week fourth fiscal quarter and 53-week full year ended December 31, 2023. The comparable period-year periods in 2022 included 13 and 52 weeks, respectively. Key highlights for the quarter ended December 31, 2023, compared to December 25, 2022:Total revenues increased by 4.7% to $125.7 million compared to $120.2 million. Average Weekly Sales (AWS) increased...

Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024 Completed enrollment into first split daily dosing cohort of the Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors Strengthened balance sheet following receipt of non-dilutive proceeds of $5.0 million through monetization of a pre-commercialization, event-based milestone from Day One Biopharmaceuticals, Inc., extending cash runway into mid-Q1 2025 SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...

SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Business Highlights:Achieved strong annual revenue growth for both proprietary product lines, with sales increasing for SimpliDerm by 38% and CanGaroo by 3.4%. Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA” or “Agency”) for CanGarooRM, Elutia’s next-generation drug-eluting biomatrix product. FDA review and interaction for CanGarooRM has resulted in no requests for additional data to date. The Company remains on track for a clearance decision in the first half of 2024. Successfully closed the divestiture of the orthobiologics business, generating gross cash...